According to the 2023 Canadian Thoracic Society guidelines on pharmacotherapy in patients
with stable COPD, all the following statements are true, EXCEPT for . . .
Study provides insight on the value of a new orally-administered, selective P2X3 receptor antagonist antitussive that is under review by Health Canada.